What FTC Victory Means For Reverse Payment Settlements

By William Lavery, Christine Ryu-Naya and Christopher Wilson (April 21, 2021, 5:58 PM EDT) -- At a time when scrutiny of pharmaceutical companies has reached new highs, a recent decision by one of the country's most conservative courts is likely to have a significant impact on future pharmaceutical patent settlements.

On April 13, in Impax Laboratories Inc. v. Federal Trade Commission, the U.S. Court of Appeals for the Fifth Circuit unanimously upheld the FTC's ruling that the reverse payment settlement agreement between Endo Pharmaceuticals Inc. and Impax Laboratories violated the antitrust laws.[1]

In doing so, the court arguably collapsed the standard for evaluating reverse payment settlements that the U.S. Supreme Court set out in its 2013 landmark decision...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!